Plasmablastic posttransplant lymphoma: Cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective german posttransplant lymphoproliferative disorder registry

Transplantation

Volumn 93, Issue 5, 2012, Pages 543-550

  Zimmermann, Heiner ^a   Oschlies, Ilske ^a   Fink, Susanne ^b   Pott, Christiane ^a   Neumayer, Hans H ^b   Lehmkuhl, Hans ^c   Hauser, Ingeborg A ^d   Dreyling, Martin ^e   Kneba, Michael ^a   Gärtner, Barbara ^f   Anagnostopoulos, Ioannis ^b   Riess, Hanno ^b   Klapper, Wolfram ^a   Trappe, Ralf U ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

Author keywords

CD138; DLBCL; MYC; Plasmablastic lymphoma; Posttransplant lymphoproliferative disorder (PTLD)

Indexed keywords

ALBUMIN; AZATHIOPRINE; BENDAMUSTINE; BLEOMYCIN; BORTEZOMIB; CALCINEURIN INHIBITOR; CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MELPHALAN; PARAPROTEIN; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CELL STRUCTURE; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE REGISTRY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEBRILE NEUTROPENIA; FEMALE; GENE LOCUS; GENE REARRANGEMENT; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; ISCHEMIC HEART DISEASE; LUNG ASPERGILLOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PERITONITIS; PLASMABLASTIC POSTTRANSPLANT LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; CHROMOSOME ABERRATIONS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE REARRANGEMENT; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84857656743     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318242162d     Document Type: Article

References (34)

1. Penn I, Hammond W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1:106.
2. Swerdlow SH, Webber SA, Chadburn A, et al. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoetic and lymphoid tissues. Lyon, France, IARC 2008, p 343.
3. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901.
4. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: Results of a prospective multicentre phase II study. Blood 2006;107:3053.
5. Zimmermann H, Trappe R. Therapeutic options in post-transplant lymphoproliferative disorders. Ther Adv Hematol 2011; Epub ahead of print; DOI 10.1177/2040620711412417. http://tah.sagepub.com/content/early/2011/09/09/ 2040620711412417.abstract.
6. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413.
7. Borenstein J, Pezzella F, Gatter KC. Plasmablastic lymphomas may occur as post-transplant lymphoproliferative disorders. Histopathology 2007;51:774.
8. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004;28:736.
9. Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBVassociated lymphoproliferative disorders in the Western population: A spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011;117:4726.
10. Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France, IARC 2008, p 256.
11. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, et al. Aggressive large B-cell lymphoma with plasma cell differentiation: Immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010;95:1342.
12. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010;34:1686.
13. Vrzalikova K, Vockerodt M, Leonard S, et al. Down-regulation of BLIMP1+ by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: Implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 2011;117:5907.
14. Vereide DT, Sugden B. Lymphomasdiffer in their dependence on Epstein-Barr virus. Blood 2011;117:1977.
15. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. Am J Hematol 2008;83:804.
16. Bibas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 2010;28:e704.
17. Nicol I, Boye T, Carsuzaa F, et al. Post-transplant plasmablastic lymphoma of the skin. Br J Dermatol 2003;149:889.
18. Verma S, Nuovo GJ, Porcu P, et al. Epstein-Barr virus-and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation. J Cutan Pathol 2005;32:35.
19. Trappe R, Choquet S, Oertel S H K, et al. Sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial. ASH Annual Meeting Abstracts 2009;114:100.
20. Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: From harmless to life endangering virus-lymphocyte interactions. Oncogene 2007;26:1297.
21. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360.
22. Bogusz AM, Seegmiller AC, Garcia R, et al. Plasmablastic lymphomas with MYC/IgH rearrangement: Report of three cases and review of the literature. Am J Clin Pathol 2009;132:597.
23. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997;276:596.
24. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001;19:772.
25. Timms JM, Bell A, Flavell JR, et al. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: Similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003;361:217.
26. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 2011;11:336.
27. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038.
28. Choquet S, Oertel S, Le Blond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution. Ann Hematol 2007;86:599.
29. Almenar L, Segovia J, Crespo-Leiro MG, et al. Spanish Heart Transplantation Registry. 21st Official Report of the Spanish Society of Cardiology Working Group on Heart Failure and Heart Transplantation (1984-2009). Rev Esp Cardiol 2011;63:1317.
30. Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like posttransplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease-A prospective analysis of 8 cases. Haematologica 2011;96:1067.
31. Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: A clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004;15:1673.
32. Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008;13:563.
33. Hinrichs C, Wendland S, Zimmermann H, et al. IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: A longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transpl Int 2011;24:892.
34. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 2006;8:141.